OptimizeRx price target lowered to $7 from $14 at RBC Capital
The Fly

OptimizeRx price target lowered to $7 from $14 at RBC Capital

RBC Capital lowered the firm’s price target on OptimizeRx (OPRX) to $7 from $14 but keeps an Outperform rating on the shares. The company’s Q3 revenue missed consensus on a macro shift affecting the DTC business and its FY24 guidance was adjusted lower, though on the brighter side, momentum on the HCP – healthcare professionals – side continues to strengthen, with the management having noted meaningful pipeline growth and progress, the analyst tells investors in a research note.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App